inVentiv, Median strategic alliance brings biomarker imaging to clinical trials
Anne Pilling, SVP, Global Project Management of inVentiv Health told Outsourcing-Pharma.com the strategic alliance will provide its customers with “the most advanced imaging biomarkers, at a time when 73% of cancer compounds in clinical trials involve biomarkers in their research and development design.”
inVentiv Health clients will gain access to the imaging solutions and services provider’s technology for early- to late-stage oncology trials.
“No matter where our clients are in development, we’ll be able to provide support,” said Pilling.
Early-stage clients will have access to integrated imaging services to access imaging biomarkers. For late-stage clients, Median’s management services technology will provide data integrity, reliability, and transparency.
“Our clients are increasingly looking to us to provide them with innovative solutions to increase the efficiency of and accelerate the clinical trial process,” explained Pilling.
“The measurement of imaging biomarkers is a critical component of oncology research and demand for an improved methodology is high," she added.
"We believe that Median’s technology offers a smarter solution that will be welcomed by our oncology clients.”